Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice

Abstract

Etanercept is well tolerated and effective in moderate to severe psoriasis; however, data on patient-reported outcomes (PROs) in Canadian patients remain limited. To assess PROs in Canadian patients with moderate to severe psoriasis receiving etanercept in an open-label trial more representative of general clinical practice than traditional research studies. This 1-year, multicenter, single-arm study enrolled 246 patients. Patients received etanercept 50 mg subcutaneously twice weekly for 3 months and then 50 mg once weekly for 9 months. Primary and safety end points were reported previously. Change from baseline to month 12 for the Dermatology Life Quality Index (DLQI), EuroQoL-5D, and Treatment Satisfaction Questionnaire for Medication (TSQM) are secondary outcomes reported here. Post hoc analyses of PROs are also reported. Mean ± standard deviation (SD) DLQI total score improved from 13.7 ± 6.1 at baseline to 3.9 ± 5.6 at month 12. By month 12, 75% of patients achieved a clinically meaningful improvement in the DLQI (≥ 5-point improvement or a score of 0). Fifty-three to 86% of patients reported improvement or complete improvement in the six DLQI subscales. The mean ± SD EuroQoL-5D total score improved from baseline (0.67 ± 0.25) to month 12 (0.83 ± 0.25). The TSQM scores showed improvement in global satisfaction, effectiveness, and convenience after 3 months. Etanercept was associated with improved PROs and increased treatment satisfaction over 1 year.